What anti-obesity medications are in development? How does the potential approval of newer anti-obesity medications fit within the paradigm of obesity clinical practice, as outlined by the Obesity Medicine Association (OMA) Clinical Practice Statements and Position Statements? What are the cardiovascular disease implications? Clinicians are well aware of the seismic change in both clinical practice, and in the societal environment with the recent approval of highly effective anti-obesity medications. However, currently approved anti-obesity medications are just the start of a revolution in obesity pharmacotherapy. In this scientific session, Dr. Harold Bays (OMA Chief Science Officer and Editor-in-Chief of Obesity Pillars) will explore his 30-year experience as a clinical trialist of over 600 clinical trials. He will describe the cardiovascular disease implications of ongoing anti-obesity medication clinical trials. He will also explore anti-obesity drugs in the pipeline, that include (among others), novel glucagon-like peptide 1 (GLP-1) based pharmacotherapies such as combination GLP-1 & GIP receptor agonists (RA), GLP-1 RA & glucagon RA, GLP-1 RA & GIP receptor antagonists, oral GLP-1 RA, small molecule/non-peptide GLP-1 RA, GLP-1 RA & amylin analogues, triple GLP-1 RA/glucagon RA/GIP RA, GLP-1RA & peptide YY RA, as well as oxyntomodulin-acting and "gut-brain axis" agents.

CME/CE Expiration Date: 4/26/27

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.